

Gerard Sanacora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8963395/publications.pdf>

Version: 2024-02-01

131
papers

20,767
citations

13099

68
h-index

15266

126
g-index

135
all docs

135
docs citations

135
times ranked

15250
citing authors

#	ARTICLE	IF	CITATIONS
1	The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. <i>Nature Reviews Neuroscience</i> , 2012, 13, 22-37.	10.2	1,147
2	Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. <i>Nature Medicine</i> , 2016, 22, 238-249.	30.7	1,128
3	Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications. <i>Biological Psychiatry</i> , 2008, 64, 527-532.	1.3	1,070
4	Towards a glutamate hypothesis of depression. <i>Neuropharmacology</i> , 2012, 62, 63-77.	4.1	831
5	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 426-437.	46.4	761
6	Subtype-Specific Alterations of $\hat{1}^3$ -Aminobutyric Acid and Glutamate in Patients With Major Depression. <i>Archives of General Psychiatry</i> , 2004, 61, 705.	12.3	704
7	Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. <i>Neuron</i> , 2019, 102, 75-90.	8.1	554
8	Reduced Cortical $\hat{1}^3$ -Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy. <i>Archives of General Psychiatry</i> , 1999, 56, 1043.	12.3	547
9	Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2018, 175, 620-630.	7.2	496
10	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , 2018, 175, 150-158.	7.2	476
11	Reduced brain serotonin transporter availability in major depression as measured by [123 I]-2 $\hat{1}^2$ -carbomethoxy-3 $\hat{1}^2$ -(4-iodophenyl)tropane and single photon emission computed tomography. <i>Biological Psychiatry</i> , 1998, 44, 1090-1098.	1.3	456
12	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 399.	11.0	433
13	Increased Occipital Cortex GABA Concentrations in Depressed Patients After Therapy With Selective Serotonin Reuptake Inhibitors. <i>American Journal of Psychiatry</i> , 2002, 159, 663-665.	7.2	426
14	Increased Cortical GABA Concentrations in Depressed Patients Receiving ECT. <i>American Journal of Psychiatry</i> , 2003, 160, 577-579.	7.2	414
15	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 816-826.	7.2	388
16	Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond. <i>Biological Psychiatry</i> , 2013, 73, 1133-1141.	1.3	355
17	Riluzole Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: An Open-Label Trial. <i>Biological Psychiatry</i> , 2005, 58, 424-428.	1.3	344
18	Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. <i>Neuropsychopharmacology</i> , 2017, 42, 193-215.	5.4	343

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 121-141.	1.2	325
20	Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics. <i>Annual Review of Medicine</i> , 2015, 66, 509-523.	12.2	316
21	A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. <i>Biological Psychiatry</i> , 2000, 47, 332-337.	1.3	279
22	Lower synaptic density is associated with depression severity and network alterations. <i>Nature Communications</i> , 2019, 10, 1529.	12.8	277
23	Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	273
24	Ketamine: A Paradigm Shift for Depression Research and Treatment. <i>Neuron</i> , 2019, 101, 774-778.	8.1	271
25	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	7.2	270
26	Beyond Monoamines: Glutamatergic Function in Mood Disorders. <i>CNS Spectrums</i> , 2005, 10, 808-819.	1.2	254
27	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	7.9	235
28	Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses. <i>Biological Psychiatry</i> , 2013, 74, 742-749.	1.3	233
29	Overview of glutamatergic neurotransmission in the nervous system. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 656-664.	2.9	224
30	Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. <i>Nature Neuroscience</i> , 2021, 24, 954-963.	14.8	207
31	From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders. <i>Biological Psychiatry</i> , 2013, 73, 1172-1179.	1.3	201
32	Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms. <i>Biological Psychiatry</i> , 2007, 61, 822-825.	1.3	189
33	Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. <i>Biological Psychiatry</i> , 2012, 72, e27-e28.	1.3	187
34	N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. <i>Psychopharmacology</i> , 2006, 184, 254-256.	3.1	183
35	The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. <i>Psychiatry Research - Neuroimaging</i> , 2011, 191, 122-127.	1.8	170
36	The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?., 2018, 190, 148-158.		160

#	ARTICLE	IF	CITATIONS
37	Intravenous arketamine for treatment-resistant depression: open-label pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 577-582.	3.2	159
38	Glutamate Metabolism in Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2014, 171, 1320-1327.	7.2	155
39	Riluzole in the Treatment of Mood and Anxiety Disorders. <i>CNS Drugs</i> , 2008, 22, 761-786.	5.9	150
40	KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. <i>Depression and Anxiety</i> , 2016, 33, 689-697.	4.1	150
41	The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. <i>Neuropsychopharmacology</i> , 2018, 43, 2154-2160.	5.4	146
42	Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 292-308.	3.8	145
43	Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	145
44	Reduced Density of Calbindin Immunoreactive GABAergic Neurons in the Occipital Cortex in Major Depression: Relevance to Neuroimaging Studies. <i>Biological Psychiatry</i> , 2010, 67, 465-470.	1.3	144
45	Elevated Cerebrospinal Fluid Substance P Concentrations in Posttraumatic Stress Disorder and Major Depression. <i>American Journal of Psychiatry</i> , 2006, 163, 637-643.	7.2	136
46	Antidepressant-Like Effects of Ceftriaxone in Male C57BL/6J Mice. <i>Biological Psychiatry</i> , 2007, 61, 250-252.	1.3	136
47	Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?. <i>Neuropsychopharmacology</i> , 2015, 40, 259-267.	5.4	132
48	Impairment of GABAergic Transmission in Depression: New Insights from Neuroimaging Studies. <i>Critical Reviews in Neurobiology</i> , 2000, 14, 23.	3.1	132
49	A randomized proof-of-mechanism trial applying the "fast-fail" approach to evaluating μ -opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020, 26, 760-768.	30.7	129
50	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. <i>Neuropsychopharmacology</i> , 2020, 45, 990-997.	5.4	127
51	Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. <i>Biological Psychiatry</i> , 2012, 72, 964-970.	1.3	121
52	A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. <i>Drug Discovery Today</i> , 2019, 24, 606-615.	6.4	120
53	¹ H-[¹³ C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. <i>Biological Psychiatry</i> , 2012, 71, 1022-1025.	1.3	114
54	Sex, GABA, and nicotine: The impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. <i>Biological Psychiatry</i> , 2005, 57, 44-48.	1.3	111

#	ARTICLE	IF	CITATIONS
55	GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action. <i>CNS and Neurological Disorders - Drug Targets</i> , 2007, 6, 127-140.	1.4	110
56	Cortical \hat{I}^3 -Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy. <i>Biological Psychiatry</i> , 2006, 59, 284-286.	1.3	102
57	Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. <i>Neuropsychopharmacology</i> , 2017, 42, 844-853.	5.4	99
58	Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 162-167.	8.8	94
59	Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting. <i>Journal of ECT</i> , 2012, 28, 157-161.	0.6	93
60	Sex Differences in Diencephalon Serotonin Transporter Availability in Major Depression. <i>Biological Psychiatry</i> , 2006, 59, 40-47.	1.3	88
61	A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. <i>American Journal of Psychiatry</i> , 2017, 174, 695-696.	7.2	88
62	Antidepressant Effect of Ketamine During ECT. <i>American Journal of Psychiatry</i> , 2005, 162, 1385-1386.	7.2	87
63	Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. <i>Biological Psychiatry</i> , 2004, 56, 497-502.	1.3	83
64	Elevated Cerebrospinal Fluid Substance P Concentrations in Posttraumatic Stress Disorder and Major Depression. <i>American Journal of Psychiatry</i> , 2006, 163, 637.	7.2	83
65	In Vivo Ketamine-Induced Changes in [11 C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. <i>Biological Psychiatry</i> , 2015, 77, 266-275.	1.3	82
66	Cortical GABA Levels in Primary Insomnia. <i>Sleep</i> , 2012, 35, 807-814.	1.1	81
67	Characterization of GABAergic Marker Expression in the Chronic Unpredictable Stress Model of Depression. <i>Chronic Stress</i> , 2017, 1, 247054701772045.	3.4	81
68	Addition of the \hat{I}^2 -Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. <i>Neuropsychopharmacology</i> , 2004, 29, 1166-1171.	5.4	79
69	Targeting glial physiology and glutamate cycling in the treatment of depression. <i>Biochemical Pharmacology</i> , 2009, 78, 431-439.	4.4	78
70	Intravenous Ethanol Infusion Decreases Human Cortical \hat{I}^3 -Aminobutyric Acid and N-Acetylaspartate as Measured with Proton Magnetic Resonance Spectroscopy at 4 Tesla. <i>Biological Psychiatry</i> , 2012, 71, 239-246.	1.3	74
71	Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. <i>Psychopharmacology</i> , 2012, 219, 805-814.	3.1	73
72	The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders. <i>Nature Reviews Neuroscience</i> , 2022, 23, 86-103.	10.2	73

#	ARTICLE	IF	CITATIONS
73	Riluzole Augmentation for Treatment-Resistant Depression. American Journal of Psychiatry, 2004, 161, 2132-2132.	7.2	64
74	Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2015, 76, 1075-1084.	2.2	63
75	Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today, 2009, 14, 690-697.	6.4	60
76	Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal of Psychiatry, 2021, 178, 352-362.	7.2	59
77	Genotype-controlled analysis of plasma dopamine β -hydroxylase activity in psychotic unipolar major depression. Biological Psychiatry, 2002, 51, 358-364.	1.3	58
78	Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biological Psychiatry, 2003, 54, 792-799.	1.3	57
79	Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 327-335.	1.5	57
80	Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder. Psychotherapy and Psychosomatics, 2014, 83, 298-307.	8.8	53
81	ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment. Journal of ECT, 2001, 17, 27-32.	0.6	52
82	Computerized ambulatory monitoring in mood disorders: Feasibility, compliance, and reactivity. Psychiatry Research, 2010, 178, 440-442.	3.3	52
83	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology, 2020, 45, 1656-1663.	5.4	50
84	Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. Journal of Clinical Psychiatry, 2018, 79, .	2.2	50
85	Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry, 2021, 26, 5097-5111.	7.9	48
86	Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 449-456.	1.5	47
87	Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry, 2002, 51, 469-473.	1.3	45
88	Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. Journal of Affective Disorders, 2018, 227, 11-16.	4.1	44
89	Chronic Riluzole Treatment Increases Glucose Metabolism in Rat Prefrontal Cortex and Hippocampus. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1892-1897.	4.3	42
90	Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychotherapy and Psychosomatics, 2021, 90, 318-327.	8.8	42

#	ARTICLE	IF	CITATIONS
91	Major depression: emerging therapeutics. Mount Sinai Journal of Medicine, 2008, 75, 204-225.	1.9	41
92	Glutamate-based depression GBD. Medical Hypotheses, 2012, 78, 675-681.	1.5	41
93	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research, 2019, 110, 166-171.	3.1	41
94	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression and Anxiety, 2019, 36, 235-243.	4.1	37
95	Cortical Inhibition, Gamma-Aminobutyric Acid, and Major Depression: There Is Plenty of Smoke but Is There Fire?. Biological Psychiatry, 2010, 67, 397-398.	1.3	36
96	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology, 2017, 42, 2567-2574.	5.4	36
97	ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials, 2019, 77, 19-26.	1.8	34
98	KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?. Depression and Anxiety, 2016, 33, 711-717.	4.1	31
99	CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics of North America, 2001, 85, 559-577.	2.5	30
100	Regulation of Extrasynaptic Glutamate Levels as a Pathophysiological Mechanism in Disorders of Motivation and Addiction. Neuropsychopharmacology, 2015, 40, 254-255.	5.4	26
101	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2020, 40, 287-292.	1.4	25
102	Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry, 2022, 27, 2273-2281.	7.9	25
103	The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms. Biological Psychiatry, 2016, 79, e65-e66.	1.3	24
104	Macro- and Microscale Stressâ€‘Associated Alterations in Brain Structure: Translational Link With Depression. Biological Psychiatry, 2021, 90, 118-127.	1.3	24
105	Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders. JAMA - Journal of the American Medical Association, 2017, 318, 793.	7.4	23
106	mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders, 2022, 303, 91-97.	4.1	22
107	Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine. American Journal of Psychiatry, 2019, 176, 249-249.	7.2	21
108	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders, 2020, 260, 131-139.	4.1	21

#	ARTICLE	IF	CITATIONS
109	Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. <i>Epilepsia</i> , 2021, 62, 1041-1056.	5.1	17
110	Do Glutamatergic Agents Represent a New Class of Antidepressant Drugs? Part 1. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1473-1474.	2.2	14
111	Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. <i>American Journal of Medical Genetics Part A</i> , 2004, 124B, 81-86.	2.4	13
112	Early life stress and glutamate neurotransmission in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2020, 35, 71-80.	0.7	12
113	Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. <i>JAMA Psychiatry</i> , 2022, 79, 736.	11.0	11
114	What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2016, 73, 651.	11.0	10
115	Do Glutamatergic Agents Represent a New Class of Antidepressant Drugs? Part 2. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1604-1605.	2.2	10
116	New understanding of mechanisms of action of bipolar medications. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 5, 22-7.	2.2	10
117	Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk. <i>CNS Drugs</i> , 2021, 35, 1069-1079.	5.9	9
118	Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression?. <i>JAMA Psychiatry</i> , 2020, 77, 560.	11.0	9
119	Ketamine: A Review for Clinicians. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 243-250.	0.8	7
120	Delayed Amnesic Syndrome after Riluzole Use in Major Depressive Disorder: A Case Report. <i>Psychosomatics</i> , 2013, 54, 488-492.	2.5	6
121	Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. <i>Focus (American Psychiatric Publishing)</i> , 2022, 20, 241-251.	0.8	6
122	Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine's Rapid Onset Antidepressant Actions in Rodent Models. <i>Biological Psychiatry</i> , 2018, 84, 7-8.	1.3	3
123	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. <i>Biological Psychiatry</i> , 2016, 80, 84-86.	1.3	2
124	Authorship Credit for Large Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 722.	7.4	2
125	Reviewing Medications for Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e02.	2.2	2
126	Ketamine for the Treatment of Depression—Reply. <i>JAMA Psychiatry</i> , 2017, 74, 971.	11.0	1

#	ARTICLE	IF	CITATIONS
127	Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders. , 0, , 739-749.		0
128	The Revolution in Rapid-Acting Antidepressants. Biological Psychiatry, 2013, 73, 1123-1124.	1.3	0
129	Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies. , 2014, , 313-341.		0
130	The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. , 2019, , 401-413.		0
131	A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized 1H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an $\alpha 7$ Nicotinic Acetylcholine Receptor Positive Allosteric Modulator. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020,...	1.5	0